The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase
III clinical trial to evaluate efficacy and safety of pyramax in mild to moderate COVID-19
patients.